Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(4):236-8
Article Links
Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicenter Epidemiological and Clinical Study
Theofanis Karageorgas1, Prodromos Sidiropoulos2, Dimitrios Vassilopoulos3, Dimitrios Boumpas1
Authors Information
1. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 4th Department of Medicine, National and Kapodistrian University of Athens-School of Medicine, Attikon General Hospital, Athens, Greece
2. Joint Rheumatology Program, Rheumatology and Clinical Immunology Department, University of Crete-School of Medicine, University Hospital of Heraklion, Crete, Greece
3. Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens-School of Medicine, Hippokration General Hospital, Athens, Greece
Keywords: Rheumatoid Arthritis, Interstitial Lung Disease, DMARDs
References
  1. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583-91. [https://doi.org/10.1002/art.27405] [PMID: 20155830] [PMCID: PMC4028137]
  2. Sokka T, Kautiainen H, Toloza S, Mäkinen H, Verstappen SM, Lund Hetland M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6. [https://doi.org/10.1136/ard.2006.069252] [PMID: 17412740] [PMCID: PMC2111618]
  3. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatol (Oxford) 2014;53:1676-82. [https://doi.org/10.1093/rheumatology/keu165] [PMID: 24758887]
  4. Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005;127:2019-27. [https://doi.org/10.1378/chest.127.6.2019] [PMID: 15947315]
  5. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007;175:705-11. [https://doi.org/10.1164/rccm.200607-912OC] [PMID: 17218621]
  6. Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54. [https://doi.org/10.1164/rccm.200706-877OC] [PMID: 18369202]
  7. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson, EL. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol Hoboken NJ 2017;69:542-9. [https://doi.org/10.1002/art.39971] [PMID: 27788297] [PMCID: PMC5328843]
  8. Toussirot E, Berthelot JM, Pertuiset E, Bouvard B, Gaudin P, Wendling D, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009;36:2421-7. [https://doi.org/10.3899/jrheum.090030] [PMID: 19797509]
  9. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Leflunomide Use and Risk of Lung Disease in Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis of Randomized Controlled Trials. J Rheumatol 2016;43:855-60. [https://doi.org/10.3899/jrheum.150674] [PMID: 26980577]
  10. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol Hoboken NJ 2014;66:803-12. [https://doi.org/10.1002/art.38322] [PMID: 24757133]
  11. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1074-81. [https://doi.org/10.1002/art.23913] [PMID: 18668604]
  12. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258-65. [https://doi.org/10.1016/S0140-6736(14)61704-9] [PMID: 25975452] [PMCID: PMC4580232]
  13. Rojas-Serrano J, González-Velásquez E, Mejía M, Sánchez-Rodríguez A, Carrillo G. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment Reumatol Clin 2012;8:68-71. [https://doi.org/10.1016/j.reuma.2011.12.008] [PMID: 22341526]
  14. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-9. [https://doi.org/10.1111/resp.12214] [PMID: 24286447]
  15. Fernández-Díaz C, Loricera J, Castañeda S, López-Mejías R, Ojeda-García C, Olivé A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum 2018;48(1):22-7. [https://doi.org/10.1016/j.semarthrit.2017.12.012] [PMID: 29422324]
  16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81. [https://doi.org/10.1136/ard.2010.138461] [PMID: 20699241]